Uterine artery embolization for abnormal bleeding
How to treat women with fibroids or adenomyosis, the most common myometrial causes of premenopausal abnormal uterine bleeding.
IN THIS ARTICLE
DISCHARGE INSTRUCTIONS WALLET INFO-CARD When to call your doctor
Ablation fails to ease symptoms
Lisa is a 38-year-old mother of 2 who initially reported menometrorrhagia, dysmenorrhea, urinary frequency, pelvic pressure, and increasing abdominal girth. These symptoms worsened over 3 years before Lisa saw a physician and was diagnosed with uterine fibroids. When offered hysterectomy or endometrial ablation (cryomyolysis), she chose the latter. However, her fibroids failed to shrink, and her symptoms returned 5 months after the procedure.
Lisa heard about uterine artery embolization (UAE) through the media and now asks about it. Her uterus is 20-week size with an irregular contour. Magnetic resonance imaging (MRI) shows a single large fibroid filling the uterus. Her hematocrit is 22.
Is uterine UAE right for her?
Menorrhagia and a “boggy” uterus
Angelina, 35, has 2 children and a 10-year history of menorrhagia, dysmenorrhea, and anemia. Pelvic examination reveals a 10-week size, “boggy” uterus, and MRI shows global enlargement of the uterus with a thickened junctional zone, which is characteristic of adenomyosis.
Her previous physician recommended hysterectomy after medical therapy failed, but Angelina is reluctant to undergo surgery.
Is UAE an option?
Both women are very likely to benefit from UAE, since the ideal candidate is premenopausal with symptomatic fibroids and/or adenomyosis and has either failed medical or surgical therapy or wants or needs to avoid surgery.1-11
This article describes the therapeutic role of UAE in women with abnormal uterine bleeding (AUB) due to uterine fibroids and/or adenomyosis—the most frequent myometrial causes of premenopausal AUB.
Other, less frequent myometrial disorders (eg, hypervascular pathologies such as intramyometrial and parametrial vascular malformations or neoplasms) can also be treated using embolization techniques. The main advantages of UAE in treating these diseases: 1-8,12,13
- Less invasive than surgery, with substantially less recovery time and lower morbidity
- Usually performed under local anesthesia and intravenous conscious sedation
- No worry about adhesions
- Virtually no blood loss or need for transfusion; UAE may be especially attractive for patients who refuse or cannot receive blood products for health or religious reasons.
Impressive success rates
UAE has demonstrated excellent technical (98% to 100%) and high clinical success rates (80% to 95%) in the treatment of fibroids.1-8,13 The clinical success rate is lower for adenomyosis (56% to 92%), but UAE often provides sufficient clinical relief to obviate surgery.9,10,13
Although UAE was not initially recommended for women desiring future fertility—because of the 4% risk of premature menopause—the pendulum is now swinging in the other direction. If the risks of myomectomy are great due to the anatomic size or position of fibroids or adenomyosis, the risk-benefit ratio may shift to UAE to allow preservation of reproductive capacity.1-8,11
Though embolization has been performed since the early 1970s for acute and chronic bleeding associated with various medical conditions,14 the first report of UAE did not come until 1995.1 Since then, the procedure has seen rapid growth worldwide, with approximately 50,000 cases performed. About 14,000 cases were performed in the US last year.2
Although our practice has no fixed size limitation, ideally a uterus less than 20 weeks’ gestational size is preferred.
- Viable pregnancy
- Active pelvic infection
- Presence of an intrauterine device (though the IUD may be removed before the rocedure)
- Undiagnosed pelvic or adnexal mass
- Pelvic malignancies such as ovarian or endometrial carcinoma
- History of pelvic radiation, since UAE may cause ischemic necrosis of the uterus and adjacent organs due to preexisting radiation-induced vasculitis with diffuse vascular narrowing.
- Renal insufficiency, though we have used gadolinium, a nonnephrotoxic MRI contrast medium, for women with high blood creatinine levels
- History of severe allergic reaction to iodinated contrast medium, though gadolinium can also be used in these patients
- Desire to preserve fertility, since it cannot be assured based on current data. However, uncomplicated pregnancies and normal deliveries have been reported after UAE, so this procedure may still be preferred for women who refuse or cannot undergo myomectomy.11
In some cases, extensive endometriosis is the cause of menorrhagia or dysmenorrhea, often coexisting with fibroids, and UAE may not be beneficial.11
Finally, a subserosal leiomyoma that is sufficiently pedunculated (attachment point 50% of the diameter) can be at risk for detachment from the uterus, a situation that may necessitate surgical intervention.11
Preop exam and imaging
At the physical examination, the fibroid uterus usually is enlarged with an irregular contour, and adenomyosis usually presents as a globally enlarged, “boggy” uterus (typically 6- to 10-weeks’ gestational size).
MRI is the preferred imaging
We prefer MRI since fibroids can be missed with ultrasound due to the limited field of view. MRI more accurately defines the size, location, and extent of disease. It also may better differentiate fibroids from adenomyosis.
MRI clearly depicts uterine zonal anatomy and enables accurate classification of individual masses by their locations: submucosal, intramural, or subserosal.
When adenomyosis is present, T2-weighted MRI demonstrates diffuse adenomyosis (about 66%) with global enlargement of the uterus and diffuse thickening of the junctional zone (at least 12 mm, highly predictive finding) with homogeneous low signal intensity. Focal adenomyosis (33%) can be seen as an illdefined, poorly marginated focal mass (adenomyoma) of low signal intensity within the myometrium.15,16
In women with fibroids, ultrasound usually demonstrates an enlarged uterus with lobulations, contour abnormality, or mass effects.
In women with adenomyosis, it usually demonstrates ill-defined, heterogeneous echotexture and small anechoic areas within the myometrium of asymmetrically enlarged uteri, with indistinct endometrial-myometrial borders and subendometrial halo thickening.15
Include endometrial biopsy
The patient should have a normal Pap test during the 12 months leading up to UAE, 11 and should undergo endometrial biopsy to exclude carcinoma.
Laboratory tests should include a complete blood count, blood urea nitrogen/creatinine, follicle-stimulating hormone, human chorionic gonadotropin, and coagulation tests.
UAE begins with insertion of a small catheter (4-5 French) through a femoral artery in conjunction with percutaneous angiography. The catheter is guided into the uterine arteries—left first, then right— and contrast medium is injected into each artery to confirm the position of the catheter and the presence of fibroids or adenomyosis, which appear as hypervascular lesions in angiograms (see above, right).
UAE usually requires 1 to 2 hours.
Polyvinyl alcohol (PVA) particles or trisacryl gelatin microspheres, usually 500 to 700 and/or 700 to 900 microns in size, are released through the catheter into the uterine arteries. These agents block the blood vessels that feed the fibroids and/or adenomyosis, causing them to shrink. The agents are biocompatible and have been approved by the US Food and Drug Administration.
Other, less frequently used embolic agents include gelatin sponge particles (which are temporary) and coils (which are permanent). Coils are generally used for conditions such as arteriovenous malformations or fistulae, which have large feeding vessels (iliac or enlarged uterine or ovarian vessels). This fluoroscopy-guided procedure usually is performed under local anesthesia and conscious sedation or, less often, epidural anesthesia.
Conscious sedation, NSAIDs, and antibiotics
Intravenous conscious sedation in conjunction with nonsteroidal anti-inflammatory drugs (NSAIDs) usually provides sufficient pain relief.
In addition, intravenous broad-spectrum antibiotics are used as prophylaxis for infection linked to the embolization itself and to subsequent ischemia of the fibroids and uterus.
Managing postop pain syndrome
More than 90% of women experience postembolization syndrome, which includes moderate to severe abdominal pain/cramping and nausea and vomiting in the first several hours following the procedure. As a result, they may require hospitalization (less than 24 hours) for pain management. In our experience, few women stay in the hospital more than 1 day.
A patient-controlled analgesia pump and NSAIDs are used in women with abdominal/pelvic cramping and pain (more than 90% of cases) if epidural anesthesia is not used for pain.
Low-grade fever and leukocytosis are not uncommon after embolization, and are usually treated with acetaminophen. Other symptoms are anorexia and fatigue, but they gradually subside within 3 to 4 days.
Oral NSAIDs and narcotics are often needed for several days. Many women resume light activities in a few days, and most return to normal activities within 1 week.11
Give her comprehensive discharge instructions on taking medications, what to expect, and when to contact a doctor. Follow-up visit in 1 to 4 weeks. We schedule an outpatient visit 1 to 4 weeks after the procedure. At this visit, we confirm healing of the puncture sites, screen for unusual symptoms or potential problems, and repeat follow-up instructions.11
We then follow the patient periodically (3, 6, and 12 months) to monitor her for symptoms and complications such as late infections, expulsion of infarcted fibroids, chronic endometritis, chronic vaginal discharge, and cessation or irregularity of menses, all of which have been observed after UAE.11
Transvaginal ultrasound is usually performed 3 to 6 months and 1 year after UAE to determine whether existing fibroids have been infarcted and begun to decrease in volume. It also reveals any uterine or adnexal complications.
In addition, this imaging provides a new baseline measurement of fibroid volume, against which any subsequent increase in size (which may indicate regrowth of fibroids or undiagnosed leiomyosarcoma) can be compared.11
Key findings of outcome studies
Two large series reported significant improvement in AUB in 77% to 90% of fibroid cases, and bulk-related symptoms were controlled in 86% to 91%.6-8 In these studies, average uterine volumes decreased by 35% and 58% at 3 and 12 months, respectively, with dominant fibroid shrinkage of 42%. Several large series also reported high patient satisfaction (91% to 93%) and significant improvement in quality-of-life measures. 4,6-8
Side effects and complications
Although UAE is considered very safe, it carries some risks. Spies et al 17 reported on complications in 400 consecutive patients undergoing UAE for fibroids at their institution:
- 1.25% serious complication rate
- 5% overall periprocedural morbidity rate
- no deaths and no major permanent injuries
In addition, 1 patient required hysterectomy as a result of a complication, and 1 patient had an undiagnosed leiomyosarcoma, which was discovered during an elective myomectomy 31 months after UAE.
Goldberg et al 18 reported another case with delayed diagnosis of leiomyosarcoma following UAE. In our series of 705 patients, 1 had an undiagnosed leiomyosarcoma, which presented as a pelvic mass 15 months after UAE. She subsequently underwent hysterectomy.
When to suspect leiomyosarcoma
Unlike hysterectomy or myomectomy, no tissue is obtained in UAE for pathologic diagnosis to exclude leiomyosarcoma, which is found in approximately 0.1% to 0.4% of women with fibroids and is difficult to differentiate from a benign leiomyoma using clinical tests or imaging.17-18
Suspect leiomyosarcoma if the fibroids continue to grow even after technically successful embolization.
Infection is rare, but can be lethal
A small number of patients have experienced infection, which usually is controlled with antibiotics. In a series of 414 UAE procedures in 410 fibroid patients, Rajan et al 19 reported: